Biblio

Found 23 results
Filters: Keyword is Pain  [Clear All Filters]
2023
Varga BR, Streicher JM, Majumdar S.  2023.  Strategies towards safer opioid analgesics-A review of old and upcoming targets.. Br J Pharmacol. 180(7):975-993.
2022
Starling AJ, Cortez MM, Jarvis NR, Zhang N, Porreca F, Chong CD, Schwedt TJ.  2022.  Cutaneous heat and light-induced pain thresholds in post-traumatic headache attributed to mild traumatic brain injury.. Headache. 62(6):726-736.
Watanabe M, Kopruszinski CM, Moutal A, Ikegami D, Khanna R, Chen Y, Ross S, Mackenzie K, Stratton J, Dodick DW et al..  2022.  Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine.. Brain. 145(8):2894-2909.
Navratilova E, Oyarzo J, Anderson T, Broide RS, Subramaniam SR, Vazquez-Cintron EJ, Brin MF, Schwedt TJ, Dodick DW, Porreca F.  2022.  Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache.. Cephalalgia. 42(11-12):1194-1206.
2021
LaVigne JE, Hecksel R, Keresztes A, Streicher JM.  2021.  Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity.. Sci Rep. 11(1):8232.
2019
Thompson AL, Largent-Milnes TM, Vanderah TW.  2019.  Animal Models for the Study of Bone-Derived Pain.. Methods Mol Biol. 1914:391-407.
Khanna R, Patwardhan A, Yang X, Li W, Cai S, Ji Y, Chew LA, Dorame A, Bellampalli SS, Schmoll RW et al..  2019.  Development and Characterization of An Injury-free Model of Functional Pain in Rats by Exposure to Red Light.. J Pain. 20(11):1293-1306.
2018
Streicher JM, Bilsky EJ.  2018.  Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.. J Pharm Pract. 31(6):658-669.
2016
Cowell SM, Lee YSun.  2016.  Biphalin: The Foundation of Bivalent Ligands.. Curr Med Chem. 23(29):3267-3284.
Remesic M, Lee YSun, Hruby VJ.  2016.  Cyclic Opioid Peptides.. Curr Med Chem. 23(13):1288-303.
Deekonda S, Cole J, Sunna S, Rankin D, Largent-Milnes TM, Davis P, BassiriRad NM, Lai J, Vanderah TW, Porecca F et al..  2016.  Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations.. Bioorg Med Chem Lett. 26(1):222-7.
Ramos-Colon CN, Lee YSun, Remesic M, Hall SM, LaVigne J, Davis P, Sandweiss AJ, McIntosh MI, Hanson J, Largent-Milnes TM et al..  2016.  Structure-Activity Relationships of [des-Arg(7)]Dynorphin A Analogues at the κ Opioid Receptor.. J Med Chem. 59(22):10291-10298.
2015
Giri AKumar, Apostol CR, Wang Y, Forte BL, Largent-Milnes TM, Davis P, Rankin D, Molnar G, Olson KM, Porreca F et al..  2015.  Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.. J Med Chem. 58(21):8573-83.
Majuta LA, Longo G, Fealk MN, McCaffrey G, Mantyh PW.  2015.  Orthopedic surgery and bone fracture pain are both significantly attenuated by sustained blockade of nerve growth factor.. Pain. 156(1):157-65.
2014
Zhang Y, Braithwaite A, Yuan Y, Streicher JM, Bilsky EJ.  2014.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.. Eur J Pharmacol. 736:124-30.
Hegarty DM, Hermes SM, Largent-Milnes TM, Aicher SA.  2014.  Capsaicin-responsive corneal afferents do not contain TRPV1 at their central terminals in trigeminal nucleus caudalis in rats.. J Chem Neuroanat. 61-62:1-12.
2013
Largent-Milnes TM, Brookshire SW, Skinner DP, Hanlon KE, Giuvelis D, Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S et al..  2013.  Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.. J Pharmacol Exp Ther. 347(1):7-19.
Lozano-Ondoua AN, Symons-Liguori AM, Vanderah TW.  2013.  Cancer-induced bone pain: Mechanisms and models.. Neurosci Lett. 557 Pt A:52-9.
Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom AP et al..  2013.  Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.. J Bone Miner Res. 28(1):92-107.
2012
Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV.  2012.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.. J Neuroimmunol. 244(1-2):23-31.
2010
Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, Jimenez-Andrade JMiguel, Mantyh PW, Vanderah TW.  2010.  A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.. Life Sci. 86(17-18):646-53.
Largent-Milnes TM, Vanderah TW.  2010.  Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin Ther Pat. 20(3):291-305.
2008
Vanderah TW, Largent-Milnes T, Lai J, Porreca F, Houghten RA, Menzaghi F, Wisniewski K, Stalewski J, Sueiras-Diaz J, Galyean R et al..  2008.  Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors.. Eur J Pharmacol. 583(1):62-72.